SMYD3 and lung adenocarcinoma: Moreover, in mouse models of Ras-induced lung adenocarcinoma, loss of SMYD3 augments the effectiveness of trametinib in blocking tumorigenesis (18), highlighting the possibility of combined therapies that may evade resistance.